The anti-obesity effects of resveratrol shown in rodents are not transposed into an efficient therapy of human obesity. Consequently, the search for molecules mimicking or surpassing resveratrol actions is ongoing. The natural phenolic compound pterostilbene exhibits beneficial health effects and has the capacity to limit fat mass in animal models. In this study, we tested whether pterostilbene modulates triacylglycerol accumulation/breakdown. Prolonged exposure to pterostilbene or resveratrol inhibited adipocyte differentiation in 3T3-F442A preadipocytes. Acute effects on lipolysis, antilipolysis and lipogenesis were determined for pterostilbene in mouse adipocytes, and compared with resveratrol. Pterostilbene was also tested on glycerol release and glucose uptake in subcutaneous human adipocytes. Dose-response analyses did not reveal a clear lipolytic effect in both species. The antilipolytic effect of insulin was improved by pterostilbene at 1-10 μM in mouse fat cells only, while at 1 mM, the phenolic compound was antilipolytic in human fat cells in a manner not additive to insulin. Pterostilbene dose-dependently inhibited glucose incorporation into lipids similarly to resveratrol and caffeine. However, only the former did not inhibit insulin-stimulated glucose uptake. Indeed, pterostilbene abolished the insulin lipogenic effect without inhibiting its antilipolytic action and rapid activation of glucose uptake. Pterostilbene therefore exhibits a unique panel of direct interactions with adipocytes that relies on its reported anti-obesity and antidiabetic properties.
INTRODUCTION
Among the multiple benefits of resveratrol (Vang et al., 2011) , its anti-obesity effects evidenced during experimental treatments of rodent models of obesity are still not successfully transposed to the treatment of obese subjects (reviewed in: (Fernandez-Quintela et al., 2016) ). However, the adipose cells are targets recognized to exhibit both short-term and long-term responses after acute and prolonged exposure to this polyphenol. Resveratrol induces inhibition of preadipocyte differentiation (Park et al., 2008; Li et al., 2016) , while it reduces lipogenesis and increases lipolysis in adipocytes (Szkudelska et al., 2009b) , including human fat cells (Gomez-Zorita et al., 2013b) . Indeed, the apparent lack of anti-obesity action of resveratrol in humans probably relies on its poor bioavailability (Walle et al., 2004) rather than its capacity to modulate adipocyte functions, because the molecule rapidly undergoes glucuronidation and sulfation once ingested (Otake et al., 2000) . When occurring in the 3 0 and 5 0 position on the rings, substitution of the hydroxyls of resveratrol by methoxy groups generates another natural stilbene known as pterostilbene. This dimethylether derivative of resveratrol shows higher oral bioavailability than its parent polyphenol (Kapetanovic et al., 2011) . Thus, pterostilbene exhibits reduced hepatic metabolism and markedly higher peak serum concentration and circulating values after oral administration (reviewed in: (Kosuru et al., 2016) ). Moreover, pterostilbene is generally safe for oral supplementation in humans up to 250 mg/day (Riche et al., 2013) and shares with resveratrol potent antioxidant characteristics (Dong et al., 2015) . Although pterostilbene is almost absent from wines, when compared with resveratrol, it is found in almonds, peanuts and various berries and has been the subject of extensive research (Roupe et al., 2006) . Recently, pterostilbene has been demonstrated to exert an anti-obesity effect in diet-induced or genetic models of obesity (Etxeberria et al., 2017) .
The present study focuses on white adipose tissue (AT) as one of the important targets of polyphenols, and our aim was to study the direct effects of increasing doses of pterostilbene on two main metabolic functions of the adipocytes, namely lipolysis and lipogenesis. The relative accessibility of subcutaneous human AT enabled us to verify whether the properties of pterostilbene evidenced in mouse adipocytes also applied to human fat cells. Therefore, the present study is comparative in two aspects, because on the first hand, the effects of pterostilbene are compared with that of its parent polyphenol, resveratrol; while on the second hand, we assessed whether its effects on mouse adipocytes also apply to human fat cells. The following results using cell models relevant for the studies of the impact of polyphenols on health (Grootaert et al., 2015) show that increasing doses of pterostilbene reproduce several but not all the in vitro modulatory actions of resveratrol on lipolytic, lipogenic and glucose transport activities in adipocytes.
MATERIALS AND METHODS
Patients, animals and adipose tissue sampling. Samples from human subcutaneous abdominal adipose depot were obtained from 15 non-obese women undergoing reconstructive surgery at Rangueil hospital, Toulouse (France): mean body mass index 26.8 ± 1.1 kg/m 2 , mean age 44 years (range: 26-58). The surgically removed pieces of human AT were immediately transported to the laboratory following agreement of the INSERM guidelines and ethic committee. They were used for adipocyte preparation and explorations similarly to that previously described (Carpéné et al., 2016b) . C57BL6 mice of both genders were purchased at Charles River (L'Arbresle, France) and euthanized by cervical dislocation before AT collection from intra-abdominal locations following protocols approved by the animal unit of INSERM/UPS US 006 CREFRE, Toulouse, France, with agreement number C31 555 07.
Preparation of mature adipocyte suspensions. The removed AT was subjected to collagenase digestion at 37°C to obtain isolated adipose cell preparations immediately used for the assays of lipolytic, lipogenic or glucose transport activities. AT pieces were grossly minced in Krebs-Ringer salt solution pH 7.5 containing 15 mM sodium bicarbonate, 10 mM HEPES and 1 (mice) or 3.5% (humans) of fat-depleted bovine serum albumin (KRBHA), and 5.5 mM glucose, except for the cell preparations used for glucose uptake assays, in which glucose was replaced by 2 mM pyruvate. After digestion with 1 mg/mL collagenase type II for approximately 45 min under agitation, buoyant adipocytes were separated and washed in fresh KRBHA. The fat cell suspensions were then distributed as 200 (mice) or 400-μL portions (humans) to incubation plastic vials containing the final concentrations of the agents tested. These cell suspensions averaged 15 and 25 mg lipids/vial for a total of 20 and 15 preparations for mice and humans, respectively.
Assessment of lipolytic activity. All the steps allowing the incubation at 37°C of the mature adipocytes with the indicated agents were performed as previously described (Carpéné et al., 2016a) . When specified, a preincubation with the tested agents was performed 2 h prior the incubation period. After 2 h under gentle agitation, the incubations were stopped by placing the incubation tubes on ice. Once the buoyant adipocytes were frozen on the wall of the tubes, the glycerol released in the medium was determined on aliquots with the free glycerol reagent from Sigma (ref F6428, Sigma-Aldrich, St Louis, MO) while the release of free fatty acid (FFA) was assessed with Wako NEFA-HR2 kit (Wako Chemicals GmbH, Neuss, D).
Lipogenesis assay. Lipogenesis was determined by quantifying the incorporation of D-[3-3 H]-glucose into fat cell lipids, owing to slight adaptations of the original method of Moody and coworkers (Moody et al., 1974) . Adipocytes were incubated at 37°C in the same incubation medium as for lipolysis assays, except that energy was provided by an isotopic dilution of D-[3-3 H]-glucose at 0.6 mM final concentration. The same vials were used for 120-min incubation, for lipid extraction in an organic mixture for liquid scintillation that is non-miscible with water (InstaFluorPlus, PerkinElmer, Waltham, USA), and for counting the neo-synthesized radioactive lipids. The radiolabelled glucose that remained non-metabolized by the cells was restrained to the lower phase of the tubes and did not trigger any excitation of the non-water miscible scintillation cocktail as previously described (Les et al., 2016) .
Glucose transport assay. [ 3 H]-2-deoxyglucose (2-DG) uptake into fat cells was determined at 37°C in KRBHA as previously reported (Carpéné et al., 2016a) . To this aim, an isotopic dilution of 2-DG at 0.1 mM (approximately 1 300 000 dpm/vial) was incubated for 10 min with 400 μL of fat cell suspension after 45-min preincubation with the tested agents. The samples were stopped by 100 μL of 100 μM cytochalasin B, and 200 μL of cell suspension was centrifuged in microtubes containing dinonyl phthalate (density 0.98 g/mL) to separate the adipocytes from the buffer, as previously described (Carpéné et al., 2016b) . The hexose internalized in intact fat cells (upper part of the microtubes) was counted, while the extracellular 2-DG was determined in adipocytes previously blocked by cytochalasin B at time 0. This extracellular fraction did not exceed 1% of maximum 2-DG uptake in the presence of insulin, and was subtracted from all assays.
3T3 cell culture and preadipocyte treatments. 3T3 F442A cells were grown at 37°C under 5% CO 2 in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% foetal calf serum and antibiotic mixture (100 U/mL penicillin +100 μg/mL streptomycin) until confluence. Cells were then induced to differentiate by 50 nM insulin for 8 days with or without the tested polyphenols. Triacylglycerol and protein determinations were performed on post-confluent cultures as already described (Grès et al., 2013) .
Chemicals.
Pterostilbene (3,5-dimethoxy-4 0 -hydroxystilbene) was obtained from Sigma-Aldrich, as it was the case for trans-resveratrol, caffeine, isoprenaline (also known as isoproterenol) and other reagents, except otherwise stated. Phytochemicals were dissolved in dimethyl sulfoxide (DMSO, from Sigma-Aldrich) (Les et al., 2016) .
Statistical analysis. Data were compared by Student's unpaired t test after checking values for Gaussian distribution. Data are given as mean ± SEM (standard error of the mean) for n, the number of independent observations. NS: non-statistical significance. For the collected parameters, no inter-species statistical analysis was performed between human and mouse adipocytes because various factors other than the factor 'species' differed between human and mouse adipocyte experiments.
RESULTS

Verification of the anti-adipogenic effect of pterostilbene and resveratrol
Because it has been reported that long-term treatment with pterostilbene inhibits adipocyte differentiation in 3T3-L1 preadipocyte lineage (Hsu et al., 2012) , it was first verified whether our pterostilbene preparation could reproduce such anti-adipogenic activity. To this aim, preliminary tests were performed on murine 3T3-F442A cells that slightly differ from 3T3-L1 in their requirements for adipocyte differentiation. Adipogenesis of 3T3-F442A cells is only insulin dependent (Fève and Pairault, 1987) , while 3T3-L1 cells also need priming with isobutylmethylxanthine and dexamethasone. 3T3-F442A preadipocytes accumulated triacylglycerols when continuously stimulated by 50-nM insulin for eight days (positive control of adipogenesis set at 100%). The daily addition of 2-μM pterostilbene or resveratrol together with insulin for 8 days reduced this triacylglycerol accumulation (Fig. 1 ). These preliminary experiments confirmed that chronic treatment with pterostilbene fully reproduces the known anti-adipogenic effect of resveratrol.
Assessment of pterostilbene effects on lipolytic activity in mouse adipocytes
The acute effects of pterostilbene on fat cell lipolysis were then investigated on mouse adipocytes. Pterostilbene alone did not modify basal glycerol of FFA release, when tested up to 100 μM, indicating that it was not lipolytic (not shown). However, a more discriminant way to reveal putative lipolytic modulators consists in testing the studied agent in the presence of a sub-maximal dose of a lipolytic factor of reference that unmasks any further stimulatory or inhibitory response. Pterostilbene was therefore tested from 1 μM to 1 mM on the triacylglycerol breakdown stimulated by 100 nM isoprenaline. The 4.2 ± 0.9-fold increase of basal glycerol release and the 5.1 ± 1.2-fold increase of basal FFA release induced by the β-adrenergic agonist (n = 16) were not substantially modified by increasing doses of pterostilbene ( Fig. 2) . In contrast, a high dose of resveratrol (1 mM) reduced the stimulation of glycerol release induced by isoprenaline, without noticeably altering FFA release. Consequently, the FFA/glycerol ratio, which was 2.4 ± 0.1 for isoprenaline alone, was unchanged in the presence of pterostilbene (2.3 ± 0.1) but increased with 1 mM resveratrol (3.1 ± 0.2; p < 0.001; n = 16). It was also verified that DMSO, the vehicle used to solubilize the stilbenes, was without effect on these parameters.
Pterostilbene was then tested on insulin-induced antilipolysis and compared with resveratrol. In addition, caffeine, a widely known plant alkaloid recognized to inhibit glucose uptake and lipid accumulation in adipocytes (Nakabayashi et al., 2008; Colitti and Stefanon, 2016) , was included in the comparison. At 100 nM, insulin tended to lower both basal and isoprenaline-stimulated lipolysis, indicative of a partial antilipolytic effect (Fig. 3) . In these conditions, resveratrol exhibited a somewhat biphasic effect, being rather pro-lipolytic at 100 μM and antilipolytic at 1 mM, especially when measuring glycerol release. On the other hand, caffeine was clearly pro-lipolytic at 1 mM. Caffeine completely reversed the antilipolytic action of insulin and triggered a release of both glycerol and FFA that was even higher than that observed with isoprenaline alone. Pterostilbene behaved differently from the two other phytochemicals: at 1 or 10 μM, it reinforced the mild antilipolytic effect of insulin and decreased glycerol release. At higher doses, pterostilbene did not further alter the antilipolytic response to insulin even when present at 1 mM (Fig. 3) .
Lipogenesis inhibition by pterostilbene
The capacity of pterostilbene to modify de novo lipogenic activity was then compared with the known antilipogenic action of resveratrol (Carpéné et al., 2014) and caffeine (Nakabayashi et al., 2008) . The basal incorporation of radiolabelled glucose into intracellular lipids of mouse adipocytes was activated by 100 nM insulin up to a 2.6 ± 0.2-fold factor (p < 0.001, n = 20). As expected, resveratrol dose-dependently inhibited such insulin-dependent glucose incorporation into lipids, reaching a total blockade at 1 mM (Fig. 4) . Caffeine also was strongly inhibitory at 1 mM. Pterostilbene behaved similarly: it clearly inhibited glucose incorporation into lipids except at 10 μM, which exhibited a trend to increase insulin action. Moreover, we verified that the inhibitory effects observed with 1 mM of these phytochemicals were not due to DMSO vehicle, and observed that none of the antioxidants tested in parallel were capable of abolishing the insulin-dependent incorporation of glucose into lipids. Indeed, 1 mM ascorbic acid (not shown) and 1 mM N-acetyl cysteine (Fig. 4) were ineffective on insulinstimulated lipogenesis.
We then tested the combination of pterostilbene and resveratrol at 10 μM, i.e. when they exhibited almost opposite actions on insulin-induced lipogenesis. This curiously resulted in a reduction of glucose incorporation into lipids that reached 68% of the insulin effect, therefore reproducing the antilipogenic action of resveratrol alone and suggesting that their inhibitory effects were not additive (not shown).
Pterostilbene effects on lipolytic activity in human adipocytes
The effects of pterostilbene on triacyglycerol synthesis and breakdown observed in mouse adipocytes prompted us to perform similar experiments in human subcutaneous adipocytes. As with rodent adipocytes, pterostilbene alone did not alter basal lipolysis when tested on freshly isolated human fat cells, even at 1 mM (not shown). On the contrary, lipolytic activity was clearly stimulated by isoprenaline: after 2 h of stimulation, 10 nM of the β-adrenergic agonist increased glycerol release by 3.4 ± 0.4-fold (p < 0.01, n = 7). The pterostilbene influence was explored after a 2-h preincubation with human fat cells before adding the lipolytic agent isoprenaline for an additional 2 h. In these conditions, pterostilbene was practically devoid of any effect: it only exhibited a trend to reinforce the lipolytic action of isoprenaline at 100 nM and 10 μM. However, at the high dose of 1 mM, pterostilbene reduced the lipolytic effect of the β-adrenergic agonist (Fig. 5A) .
We further studied this unexpected antilipolytic behaviour of pterostilbene by comparing/combining with that of insulin and by using shorter exposure protocol consisting of a 2-h incubation with all tested agents, without any preincubation. Again, pterostilbene reduced the lipolytic effect of 10-nM isoprenaline only when present at 1 mM (Fig. 5B) . One hundred nanomolar insulin also partially inhibited the lipolytic action of isoprenaline, allowing the detection of only 52 ± 15% of the glycerol release found with the β-adrenergic agonist alone. When tested in the presence of isoprenaline and insulin, pterostilbene did not amplify the antilipolytic effect of the hormone.
It was then planned to determine the influence of pterostilbene on lipogenesis in human adipocytes. However, insulin activated by only 1.42 ± 0.27-fold the basal glucose incorporation into lipids in human subcutaneous adipocytes (NS, n = 4, not shown). Because not any tested condition was different from baseline, further experiments were cancelled, and it was decided to perform another type of exploration by comparing hexose uptake activity in both murine and human adipocytes.
Influence of pterostilbene on glucose transport in adipocytes
When tested in mouse adipocytes, 100-μM pterostilbene was unable to modify basal glucose transport or to significantly alter the dose-dependent activation by insulin (Fig. 6A) . Resveratrol behaved similarly. Both stilbenes exhibited only a trend to limit insulin stimulation of hexose transport into mouse fat cells, which attained a plateau at 100 nM and represented a 5.7 ± 1.0-fold increase over baseline (p < 0.01, n = 6). However, when tested at 10 μM, resveratrol tended to decrease insulin action, allowing the detection of 75.0 ± 8.3% of its maximal action while pterostilbene was without influence: 100.8 ± 11.9% (NS, n = 6, not shown). In contrast, caffeine, known to limit glucose uptake in adipocytes readily inhibited half of the insulin effect at 100 μM (55.2 ± 1.6%, p < 0.01, n = 3, not shown).
In human adipocytes, pterostilbene did not modify basal glucose uptake (0.20 ± 0.06 vs 0.23 ± 0.04 nmoles of 2-DG carried/10 min/100 mg lipids for basal and 0.1 mM pterostilbene, respectively, NS, n = 12). Similarly, pterostilbene could not alter a submaximal activation of glucose transport by 10 nM insulin (Fig. 6B) . Last, when present at 100 nM, insulin maximally activated up to 3.9 ± 0.6-fold the basal uptake (p < 0.001, n = 12), and 100-μM pterostilbene exhibited only a trend to inhibit less than one-quarter of glucose uptake activation (p = 0.10; Fig. 6B ). In the same conditions, only 54.7 ± 6.7% of maximal insulin effect remained in the presence of 100-μM resveratrol (p < 0.05, n = 12, not shown) and 56.2 + 4.4% in the presence of 1 mM caffeine (Fig. 6B) .
DISCUSSION
In view of the recent results showing that pterostilbene reduces fattening in obese rodents and that AT is a recognized target of and caffeine (open squares) were tested at the indicated final concentrations together with 100 nM insulin (ins). Mean ± SEM of 6 to 14 observations. Different from control at: ** p < 0.01, *** p < 0.001. A trend to inhibition is indicated by p value of 0.09 in parentheses.
resveratrol action, either in various cultured preadipocyte models (Lasa et al., 2012; Li et al., 2016; Warnke et al., 2016; Carpéné et al., 2016b) or in treated rodents (Kim et al., 2011; Gomez-Zorita et al., 2013a; Chang et al., 2016) , we aimed at comparing in adipocytes the lipolytic and lipogenic effects of these two phenolic compounds, the chemical structure of which differs by only two methoxy groups.
One could expect that polyphenols behave as strong lipolytic agents in vitro on the basis of their anti-obesity action and their ability to enhance energy expenditure in rodents (Wang et al., 2014) . This was definitively not the case in the present study because in none of the tested conditions (mouse or human fat cells, basal or stimulated levels) resveratrol and pterostilbene were clearly able to trigger or to reinforce lipolytic activity. Pterostilbene exhibited only a weak tendency to increase isoprenaline lipolytic action in mouse fat cells, somewhat reproducing the previously reported resveratrol effects (Szkudelska et al., 2009b; Lasa et al., 2012; Les et al., 2016) . Resveratrol used as a reference polyphenol in our studies even became antilipolytic in mouse adipocytes at the highest tested millimolar dose. One study performed on mouse adipocytes has similarly reported a trend of high dose of resveratrol to reduce β-adrenergic activation of lipolysis (Les et al., 2016) , while other works indicate that resveratrol at 1-100 μM is hardly lipolytic on its own and increases by only 20-50% the β-adrenergic stimulation of lipolysis (Szkudelska et al., 2009b; Lasa et al., 2012) .
In human adipocytes, the lipolytic response to pterostilbene did not display a classical (sigmoid) dose dependency, as was already the case for resveratrol (Gomez-Zorita et al., 2013b) . In addition to the lack of evidence of clear-cut lipolytic effect, our data collected here with pterostilbene in human adipocytes, and with resveratrol in mouse adipocytes, rather indicated that high millimolar doses of phenolic compounds can be antilipolytic. This was not due to the vehicle used, as demonstrated in (Les et al., 2016) and confirmed by the fact that 1 mM resveratrol limited glycerol but not FFA release in mouse adipocytes stimulated by 100 nM isoprenaline. Consequently, the FFA/glycerol ratio was higher with isoprenaline and resveratrol than with isoprenaline alone or isoprenaline and pterostilbene. This FFA/glycerol ratio, which is generally lower than the theoretical value of 3 in response to classical lipolytic agents, owing to stimulated reuptake and reesterification of fatty acids, reached the value of 3 in the presence of high dose of resveratrol. This indicated that the parent polyphenol, unlike pterostilbene, favoured an incomplete hydrolysis of triacylglycerols or inhibited FFA reesterification. The former hypothesis was in agreement with the capacity of resveratrol to activate adipose triglyceride lipase (ATGL) (Lasa et al., 2012) . Because ATGL acts upstream of the hormone-sensitive lipase (HSL) in the triacylglycerol breakdown cascade, it leads to a higher release of FFA than glycerol. Accordingly, we observed that FFA release was much more elevated than glycerol release in mouse adipocytes exposed to 1 mM resveratrol (Les et al., 2016) . Moreover, it has been reported that 100 μM resveratrol inhibits forskolin-induced glycerol release in differentiated human preadipocytes (Krawczyk et al., 2012) , also evoking a similar HSL impairment without ATGL alteration. Even when not considering the effects of these elevated, supranutritional, doses of polyphenols, our data do not support the classification of pterostilbene as a direct lipolytic activator, because in the micromolar range, it exhibited only a trend to favour the lipolytic effect of isoprenaline. Anyhow, such lack of direct lipolytic activity is not incompatible with anti-obesity properties because the phenolic compound may modulate other aspects of lipid metabolism in adipocytes. Modulation of antilipolytic rather than lipolytic activity can be another way to regulate fat store mobilization. Indeed, it is now accepted that a strong induction of lipolysis can lead to increased lipotoxicity rather than to fat store shrinking, especially when the mobilized lipids are not oxidized elsewhere in the body.
For this reason, and because insulin is limiting adipocyte lipolysis in post-prandial situations (such those following natural-or experimental-ingestion of dietary polyphenols), pterostilbene and resveratrol were tested in vitro in the presence of insulin. Pterostilbene was rather 'pro-insulinic' at low doses (≤10 μM) because it increased the partial antilipolytic action of insulin in mouse adipocytes and did not impair it in human adipocytes. However, this effect was not amplified at 2-deoxyglucose uptake in human adipocytes is expressed a percentage of the response to insulin 100 nM, with basal uptake set at 0%. Pterostilbene was incubated for 45 min alone or in the presence of 10-nM (open column, ins 10) or 100 nM insulin (striped column, ins 100), while caffeine was added at 1 mM final to 100 nM insulin (dark column). Each column is the mean ± SEM of 8 determinations. Significantly different from corresponding dose of insulin alone at: * p < 0.05.
higher doses, and-again-a lack of classical dose-response curve was evident when considering the influence of polyphenols on antilipolysis. One millimolar pterostilbene did not alter the insulin antilipolytic effect in both species studied as it was also the case for 1 mM resveratrol in humans (Gomez-Zorita et al., 2013b) or in mice when considering FFA release.
Testing millimolar doses of resveratrol or pterostilbene can be questionable regarding a possible loss of selectivity of action and occurrence of cytotoxicity. However, this was not the case for a widely recognized lipolytic factor, caffeine (Colitti and Stefanon, 2016) , that inhibited insulin antilipolytic action only at 1 mM. Thus, the high millimolar doses of the three natural compounds tested were not mandatorily loosing selectivity and cytotoxic, because each of them generated a different pattern of response. Among the wide range of concentrations tested in this study, only the higher millimolar doses, although not reachable after in vivo administration, allowed us to differentiate pterostilbene from resveratrol. Whatsoever, both polyphenols behaved differently from the reference alkaloid caffeine, the millimolar dose of which was strongly lipolytic and clearly blunted insulin antilipolytic action.
Taken together, data on adipocyte antilipolysis indicated that pterostilbene does not inhibit insulin antilipolytic action, even at 1 mM. Thus, we propose that in vivo administration of pterostilbene is not expected to deteriorate the prevention by insulin of any intense fatty acid release from AT and its deleterious consequences, namely lipotoxicity. In fact, clinical studies have indicated that pterostilbene treatment does not exhibit circulating lipid-lowering action (Riche et al., 2014) while it lowers blood cholesterol in hypercholesterolemic hamsters (Rimando et al., 2005) . Moreover, the fact that pterostilbene did not alter insulin stimulation of glucose transport in adipocytes agrees with its beneficial effect on glycaemic control observed during prolonged treatment of insulinresistant rats or hypercholesterolemic hamsters (Rimando et al., 2005) , and with its improvement of insulin action in muscles and liver .
Regarding lipogenic activity in mouse adipocytes, the comparison of the two stilbenes demonstrated that the presence of two methoxy groups in pterostilbene did not blunt the inhibitory effect found with resveratrol (Fischer-Posovszky et al., 2010) . The acute in vitro inhibition of lipid synthesis by both stilbenes deals with their anti-obesity action after prolonged supplementation in obese rodents Gracia et al., 2014; Etxeberria et al., 2017) and with their anti-adipogenic action reported here on 3T3-F442A after one-week treatment, as well as on 3T3-L1 preadipocytes (Hsu et al., 2012; Chang et al., 2016; Li et al., 2016) . Noteworthy, the long-lasting anti-adipogenic action was detected with 2 μM of pterostilbene or resveratrol while the acute effect of each agent in abolishing glucose incorporation into adipocyte lipids occurred between 100 μM and 1 mM. However, this latter rapid action could not be qualified as nonspecific because it was not observed with other natural antioxidants, such as ascorbic acid and N-acetylcysteine, while it was reproduced by caffeine, a widely consumed plant alkaloid endowed with anti-obesity and psychoactive properties (Nakabayashi et al., 2008) .
Because pterostilbene inhibits lipogenesis via AMPK activation in cancer cells and in obese rat AT , a similar mechanism could be proposed for adipocytes. Curiously, the inhibitions of glucose incorporation into lipids by micromolar doses of pterostilbene and resveratrol were not additive, while many other molecules have been already reported to act in synergism with resveratrol in inhibiting the lipid droplet formation of adipocytes (Arias et al., 2016; Warnke et al., 2016) . This lack of synergism regarding the effects of resveratrol and pterostilbene on lipid droplet replenishment can be limited to their short-term effects and does not mandatorily apply to other long-term effects such as the down-regulation of fatty acid synthase (FASN) found after 1-to 8-day exposure to 2-40 μM pterostilbene in cultured adipocytes (Hsu et al., 2012) , or the changes in methylation status of the FASN gene accompanying its down-regulation in rats treated by pterostilbene (30 mg/kg/d) for 6 weeks (Gracia et al., 2014) .
We have already reported that 100-μM resveratrol reduces the insulin stimulation of hexose transport in adipocytes isolated from human subcutaneous AT (Gomez-Zorita et al., 2013b) and from visceral AT of Swiss mice (Carpéné et al., 2015) . This inhibitory effect was less pronounced here on fat cells from C57BL6 mice. Such discrepancy is not so astonishing when considering the numerous controversies raised about resveratrol effects on glucose uptake in preadipocytes and mature fat cells, or between healthy and cancer cells. Various studies have reported hexose uptake activation (Fischer-Posovszky et al., 2010) while others have shown the opposite (Lee and Kim, 2013) or a lack of effect (Szkudelska et al., 2009a) and several observed a down-regulation of glucose transporters (Warnke et al., 2016) . To our knowledge, there is no such controversy regarding the lack of short-term influence of pterostilbene on insulin stimulation of glucose transport in fat cells. Yet, it appeared clearly that pterostilbene behaved differently from caffeine, for which we confirmed its capacity to inhibit glucose uptake in adipocytes (Nakabayashi et al., 2008) . Consequently, the clear-cut antilipogenic action of pterostilbene evidenced in mouse adipocytes was apparently not due to a blockade of the first step of the glucose incorporation into intracellular lipids, namely its handling by glucose carriers while it was likely affecting hexokinase phosphorylation rate, pyruvate formation and/or acetyl-CoA conversion into fatty acids.
Our observations indicate that pterostilbene induces anti-adipogenic actions in preadipocytes and rapidly inhibits glucose incorporation into lipids of mature adipocytes. Such antilipogenic effect is capable of occurring in vivo as evidenced in recent reports. Inhibition of FASN and acetyl-CoA carboxylase activity occurred during the adipose mass decrease found in rats after oral pterostilbene administration and likely belongs to the mechanisms reducing lipid accumulation in adipocytes without lowering glucose uptake activation by insulin. Moreover, induction of the uncoupling protein UCP1, which was recently reported in the brown AT of pterostilbene-treated obese Zucker rats , indicates that numerous steps of the pterostilbene beneficial actions are mediated by direct modulation of adipocyte metabolic functions, as those described in the present study. Consequently, pterostilbene could be considered as a candidate for the prevention of obesity, which might be as beneficial as resveratrol when used alone or in combination with other phytochemicals. Accordingly, the molecular mechanisms by which pterostilbene inhibits triacylglycerol accumulation deserve further studies.
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